Post by Hyloris Pharmaceuticals

AGM outcomes and new Chair.📰 We welcomed shareholders representing 48.50% of our Hyloris Pharmaceuticals shares at the meeting where all agenda items and proposed resolutions were approved. The Meeting also granted discharge to the members of the Board of Directors and to the statutory auditor for the financial year ending 31 December 2025. 2025 was a year of strong execution for Hyloris marked by tangible progress across development, partnering and commercialization. Looking ahead, we remain focused on disciplined execution and our go-forward commercialization strategy! 🎯 We’re pleased to share that, following more than one year as Independent Board member, Mr. Vincent Van Dessel has been appointed by the Board of Directors as the new Chairman of the Board. This change supports our governance as we continue to execute on our specialty pharma strategy: reinventing existing medicines through capital‑efficient development pathways. 💊 Full AGM documents, including the updated Remuneration Policy are available on our website. #Hyloris #Health #Pharma #ReinventingMedicines #Innovation #CorporateGovernance #Shareholders #Pharma #AGM2026